Changmeng Cai, Ph.D. - Publications

Affiliations: 
2007 The University of Toledo 
Area:
Molecular Biology, Oncology

39 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Cai C, Han D, Chen S, Han W, Gao S, Owiredu JN, Li M, Balk SP, He HH. ZBTB7A mediates the transcriptional repression activity of the androgen receptor in prostate cancer. Cancer Research. PMID 31444154 DOI: 10.1158/0008-5472.CAN-19-0815  0.68
2019 Wang Z, Gao S, Han D, Han W, Li M, Cai C. LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells. Frontiers in Oncology. 9: 721. PMID 31428587 DOI: 10.3389/fonc.2019.00721  0.32
2019 Gao S, Chen S, Han D, Barrett D, Han W, Ahmed M, Patalano S, Macoska JA, He HH, Cai C. Forkhead domain mutations in FOXA1 drive prostate cancer progression. Cell Research. PMID 31324883 DOI: 10.1038/s41422-019-0203-2  0.56
2019 Zhou F, Gao S, Han D, Han W, Chen S, Patalano S, Macoska JA, He HH, Cai C. TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells. Oncogene. PMID 30718921 DOI: 10.1038/s41388-019-0730-9  0.56
2018 Chen S, Cai C, Sowalsky AG, Ye H, Ma F, Yuan X, Simon NI, Gray NS, Balk SP. BMX-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer. Cancer Research. PMID 30012673 DOI: 10.1158/0008-5472.CAN-17-3615  0.68
2017 Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, ... ... Cai C, et al. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. Cancer Research. PMID 28916652 DOI: 10.1158/0008-5472.CAN-17-0496  0.32
2017 Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS, Mostaghel EA. Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. Molecular Cancer Research : McR. 15: 521-531. PMID 28465296 DOI: 10.1158/1541-7786.MCR-16-0315  0.36
2017 Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS, Mostaghel EA. Exploiting AR Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. Molecular Cancer Research : McR. PMID 28119432 DOI: 10.1158/1541-7786.MCR-16-0315-T  0.36
2017 Liu X, Gao Y, Ye H, Gerrin S, Ma F, Wu Y, Zhang T, Russo J, Cai C, Yuan X, Liu J, Chen S, Balk SP. Positive feedback loop mediated by protein phosphatase 1α mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic Acids Research. PMID 28062857 DOI: 10.1093/nar/gkw1291  0.68
2016 Han D, Gao S, Valencia K, Owiredu J, Han W, de Waal E, Macoska JA, Cai C. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer. Oncotarget. PMID 28036278 DOI: 10.18632/oncotarget.14296  0.32
2016 Gao S, Gao Y, He HH, Han D, Han W, Avery A, Macoska JA, Liu X, Chen S, Ma F, Chen S, Balk SP, Cai C. Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. Cell Reports. 17: 966-976. PMID 27760327 DOI: 10.1016/j.celrep.2016.09.064  0.68
2016 Ma F, Ye H, He HH, Gerrin SJ, Chen S, Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, Balk SP, Yuan X. SOX9 drives WNT pathway activation in prostate cancer. The Journal of Clinical Investigation. PMID 27043282 DOI: 10.1172/JCI78815  0.68
2016 Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel E, Nelson PS, Taplin ME, Balk SP, ... Cai C, et al. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26936914 DOI: 10.1158/1078-0432.CCR-15-2309  0.68
2015 Liu X, Han W, Gulla S, Simon NI, Gao Y, Cai C, Yang H, Zhang X, Liu J, Balk SP, Chen S. Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget. PMID 26636645 DOI: 10.18632/oncotarget.6434  0.68
2015 Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW. PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy. Cancer Research. 75: 1944-8. PMID 25808865 DOI: 10.1158/0008-5472.CAN-14-3602  0.68
2015 Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1273-80. PMID 25320358 DOI: 10.1158/1078-0432.CCR-14-1220  0.68
2014 Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4075-85. PMID 24874833 DOI: 10.1158/1078-0432.CCR-14-0292  0.68
2014 Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1590-600. PMID 24449822 DOI: 10.1158/1078-0432.CCR-13-1863  0.68
2013 Cai C, Yuan X, Balk SP. Androgen receptor epigenetics. Translational Andrology and Urology. 2: 148-157. PMID 25580383 DOI: 10.3978/j.issn.2223-4683.2013.09.02  0.68
2013 Chen S, Jiang X, Gewinner CA, Asara JM, Simon NI, Cai C, Cantley LC, Balk SP. Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Science Signaling. 6: ra40. PMID 23716717 DOI: 10.1126/scisignal.2003936  0.68
2013 Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. The Journal of Clinical Investigation. 123: 1109-22. PMID 23426182 DOI: 10.1172/JCI66666  0.68
2012 Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (New York, N.Y.). 338: 1465-9. PMID 23239736 DOI: 10.1126/science.1227604  0.68
2012 Shen HC, Shanmugasundaram K, Simon NI, Cai C, Wang H, Chen S, Balk SP, Rigby AC. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. Molecular Endocrinology (Baltimore, Md.). 26: 1836-46. PMID 23023563 DOI: 10.1210/me.2012-1222  0.68
2012 Chen S, Gulla S, Cai C, Balk SP. Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. The Journal of Biological Chemistry. 287: 8571-83. PMID 22275373 DOI: 10.1074/jbc.M111.325290  0.68
2012 Cai C, Hsieh CL, Gao S, Kannan A, Bhansali M, Govardhan K, Dutta R, Shemshedini L. Soluble guanylyl cyclase α1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer. Molecular Endocrinology (Baltimore, Md.). 26: 292-307. PMID 22174378 DOI: 10.1210/me.2010-0394  0.68
2012 Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, Swanson KD, Cai C, Balk SP, Yuan X. Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation. The Journal of Biological Chemistry. 287: 2090-8. PMID 22139837 DOI: 10.1074/jbc.M111.323303  0.68
2011 Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M, Balk SP. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 20: 457-71. PMID 22014572 DOI: 10.1016/j.ccr.2011.09.001  0.68
2011 Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Research. 71: 6503-13. PMID 21868758 DOI: 10.1158/0008-5472.CAN-11-0532  0.68
2011 Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocrine-Related Cancer. 18: R175-82. PMID 21712345 DOI: 10.1530/ERC-10-0339  0.68
2009 Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Research. 69: 6027-32. PMID 19584279 DOI: 10.1158/0008-5472.CAN-09-0395  0.68
2009 Cai C, Portnoy DC, Wang H, Jiang X, Chen S, Balk SP. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Research. 69: 5202-9. PMID 19491261 DOI: 10.1158/0008-5472.CAN-09-0026  0.68
2008 Hsieh CL, Cai C, Giwa A, Bivins A, Chen SY, Sabry D, Govardhan K, Shemshedini L. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells. Journal of Molecular Endocrinology. 41: 13-23. PMID 18469090 DOI: 10.1677/JME-07-0158  0.68
2007 Cai C, Hsieh CL, Shemshedini L. c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer. Molecular Cancer Research : McR. 5: 725-35. PMID 17634427 DOI: 10.1158/1541-7786.MCR-06-0430  0.68
2007 Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, Shemshedini L. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Molecular Endocrinology (Baltimore, Md.). 21: 1835-46. PMID 17505060 DOI: 10.1210/me.2006-0480  0.68
2007 Cai C, Omwancha J, Hsieh CL, Shemshedini L. Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells. Prostate Cancer and Prostatic Diseases. 10: 39-45. PMID 17003774 DOI: 10.1038/sj.pcan.4500912  0.68
2007 Cai C, Chen SY, Zheng Z, Omwancha J, Lin MF, Balk SP, Shemshedini L. Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation. Oncogene. 26: 1606-15. PMID 16964290 DOI: 10.1038/sj.onc.1209956  0.68
2006 Omwancha J, Zhou XF, Chen SY, Baslan T, Fisher CJ, Zheng Z, Cai C, Shemshedini L. Makorin RING finger protein 1 (MKRN1) has negative and positive effects on RNA polymerase II-dependent transcription. Endocrine. 29: 363-73. PMID 16785614 DOI: 10.1385/ENDO:29:2:363  0.68
2006 Chen SY, Cai C, Fisher CJ, Zheng Z, Omwancha J, Hsieh CL, Shemshedini L. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Oncogene. 25: 7212-23. PMID 16732317 DOI: 10.1038/sj.onc.1209705  0.68
2006 Zheng Z, Cai C, Omwancha J, Chen SY, Baslan T, Shemshedini L. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells. The Journal of Biological Chemistry. 281: 4002-12. PMID 16361251 DOI: 10.1074/jbc.M509260200  0.68
Show low-probability matches.